No abstract

BackgroundThe aim of this study was to investigate the drug survival, its efficacy and safety in patients withRA based on the database from the Turkish TURKBIO registryMethodsA total of 180 patients were treated with TOFA forRA. Drug survival was assessed. In 118 patients with available data, treatment response was evaluated using thenumber of sensitive and swollen joints, VAS values, DAS28, HAQ and CRPat weeks 12,24,48 and 60ResultsAt baseline, RA patients had a median(Q1-Q3)disease duration of 14 years.75 patients had used ≥1 biologics previously. The other demographic and clinical features of the patients were shown in table 1. Median(Q1-Q3)followup period was137 weeks. After48 and137 weeks,75% and 48%of the patients respectively, maintained TOFA (figure 1). The most common reason for drug discontinuation was ineffectiveness of treatment(63%), followed by adverse events (23%). After 12 weeks, all disease activity parameters were reduced significantly compared to the baseline and most of them continued to be reduced until week60. No difference was observed in disease activity parameters between the groups with and without previous ≥1biologics at weeks 0,12 and 24 (table 2) Remission rate was(43%)at week 60(observed data) (table 2) A total of 9 adverse events(3infection,3allergic rx,2 rash)were observed during the followup periodConclusionsTreatment with TOFA may provide good response rates in RA patients refractory previous biologicalsDisclosure of InterestNone declaredAbstract AB0482 – Table 1Week 0Week 12Week 24Week 36Week 48Week 60*p**P***p Patients with response data, (n)1183941313228Disease activity level, n (%)Remission7 (6)17 (47)10 (32)16 (59)12 (43)17 (63)Moderate64 (59)14 (39)12 (39)7 (26)10 (36)8 (30)High29 (27)1 (3)1 (3)1 (4)2 (7)2 (7)DAS28, Median (Q1-Q3)4.4 (3.7–5.1)2.8(2–3.5)3(2.4–3.6)2.2(1.9–3.3)3.1(1.9–4.2)2.1(1.9–4.1)< 0.001< 0.001< 0.001Swollen joint (0–28); Median(Q1-Q3)2 (0–4.3)00000< 0.001< 0.001< 0.001Tender joint (0–28); Median (Q1-Q3)4 (2–10)0 (0–1.3)0 (0–2)0 (0–0)0 (0–2)0 (0–0)< 0.001< 0.001< 0.001CRP (mg/L); Median (Q1-Q3)13 (4.7–29)4.8 (3–12.8)4.3 (3–10.3)4 (3–9)6 (3–12)9 (3–17.5)0.0050.0150.110Patient global score (0–100); Median62.5 (42–80)44 (12–60)30 (20 – 50)27(12–31)30.5 (15–69)27.5 (13–46)< 0.0010.001< 0.001HAQ score; Median1 (0.8–1.5)0.5 (0–1.3)0.6 (0.1–1.3)0.5 (0.3–0.8)0.6 (0.2–1.2)0.6 (0–1)0.0030.0080.001Abstract AB0482 – Table 2Disease activity parameters baseline and weeks12,24,36,48 and 60First biological tofacitinib n:105 Response data:n 581815 DAS28, Median 4.5 (3.7–5.2)2.4 (1.6 3.6)3 (2.4–3.6) (Das 28<3.1) n 11 (19%)11 (61%)8 (53%) Using other biological drugs before TOFA n:75 response data, n 501816 DAS28, Median4.4 (3.7–5)2.9 (2.4 3.5)3 (2.3–3.7) Das28<3.1 n (%) 4 (8%)10 (56%)10 (63%) #p 0.577 0.516 0.921 ##p 0.173 1.000 0.879 *p for week 0 vs 12; **p for week 0 vs 48,***p for week 0 vs 60 #p das28median for TOFA versus other biologial ##p das28 <3.1for TOFAversus other biological

Objective: Metabolic syndrome (MetS) is one of the preventable risk factors for cardiovascular disease (CVD). The aim of this study was to investigate the effect of MetS on CVD and cumulative organ damage in a multi-center, large cohort of patients with Takayasu arteritis (TAK).Methods: This is a cross-sectional study involving 192 consecutive TAK patients from seven tertiary rheumatology centers in Turkey. Clinical data of TAK patients fulfilling the 1990 American College of Rheumatology classification criteria were collected from medical records. They were evaluated for risk factors of CVD, disease activity, damage, and MetS at their last visits.Results: A total of 192 consecutive TAK patients were included in this study. One hundred and fifty-eight (82%) were female, the mean age was 43.3 ± 13 years, and mean disease duration was 13.5 ± 9.3 years. MetS was detected in 50 (26%) of the patients and CVD was detected in 28 (14.6%). The presence of MetS was detected as an independent risk factor for CVD (P < 0.001). In addition, the mean vasculitis damage index of the group with MetS was significantly higher than in the other patients (4.5 ± 3.3 vs 3.2 ± 2.2, respectively, P = 0.004). Conclusion:The presence of MetS in TAK is associated with increased CVD and disease damage. Awareness and management of MetS can improve disease prognosis in patients with TAK.

No abstract

There is a significant unmet need for effective treatment options for systemic sclerosis (SSc) because of the complexity of pathogenesis, including vasculopathy, dysregulation of innate and adaptive immunity and fibrosis. Until now, no treatment has yet proven to stop the fibrosing process of the disease and nonspecific immunosuppressive drugs including methotrexate for skin involvement, cyclophosphamide, mycophenolate mofetil (MMF) or azathioprine for lung involvement are used in treatment. 1 But these drugs have not enough capacity to prevent disease progression. New promising agents targeting fibrotic and inflammatory pathways, lymphocytes, cell-cell and